From the Journals

Keratinocyte carcinoma added no VTE risk in cohort study


 

FROM JAMA FACIAL PLASTIC SURGERY


“These results argue for careful consideration of risk assessment models, such as the Caprini score, when a surgical procedure is planned for a patient with keratinocyte carcinoma and no other risk factors for VTE in order to limit unnecessary exposure to the potential risk of VTE chemoprophylaxis,” Dr. Rudy and her coauthors wrote.

The Caprini score is a commonly used, validated, VTE risk stratification model that assigns points to specific risk factors, producing a score that can be used to decide on prophylaxis regimens, they noted.

A present or previous cancer diagnosis is worth 2 points in the Caprini system, which would put a patient at the upper end of the “low risk” category, while one additional risk factor such as planned minor surgery would indicate moderate risk.

“Recently, Caprini has begun to exclude basal cell carcinoma from this calculation, but no reference to evidence is given,” the researchers wrote.

Dr. Rudy and her coauthors had no conflicts of interest to disclose.

SOURCE: Rudy SF et al. JAMA Facial Plast Surg. 2018 May 24. doi: 10.1001/jamafacial.2018.0331.

Pages

Recommended Reading

Cancer-related clinical pearls from pediatric dermatology
MDedge Hematology and Oncology
CO2 laser guided by confocal microscopy effectively treated superficial BCC
MDedge Hematology and Oncology
New cases of Merkel cell carcinoma increased 95% between 2000 and 2013
MDedge Hematology and Oncology
HIV infection linked to higher risk of non-melanoma skin cancer
MDedge Hematology and Oncology
FDA begins priority review of cemiplimab for advanced cutaneous squamous cell carcinoma
MDedge Hematology and Oncology
Novel, noninvasive skin cancer detection device shows promise
MDedge Hematology and Oncology
Treatment of basal cell carcinoma with 1064-nm Nd:YAG laser promising
MDedge Hematology and Oncology
Patidegib, the first topical hedgehog inhibitor, scores in Gorlin syndrome
MDedge Hematology and Oncology
Cemiplimab impresses in advanced CSCC
MDedge Hematology and Oncology
Spotlight on nonmelanoma skin cancer’s true burden
MDedge Hematology and Oncology